Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr 19;7(1):1600939.
doi: 10.1080/20016689.2019.1600939. eCollection 2019.

Technology forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption

Claudia Eder  1 , Claudia Wild  1
Affiliations
Review

Technology forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption

Claudia Eder et al. J Mark Access Health Policy. .

Abstract

Background: The umbrella term ATMPs (Advanced Therapy Medicinal Products) comprises cell therapies, gene therapeutics and tissue engineered products. After implementation of the Regulation 1394/2007, only a couple of products have obtained a centralized European marketing authorisation. Objectives: The aim of the presented study is to give an overview on ATMPs available within the European Union either via centralized marketing authorisation or via national Hospital exemption. Additionally, a forecast on innovative ATMPs in the process of EMA approval as well as in phase III and IV clinical trial is provided. Methods: Systematic literature search including 'grey literature' and database reviews as well as manual search following pre-defined search terms. Results: 8 ATMPs are currently available via centralized marketing authorisation. 6 new product launches are expected before 2020. At least 32 additional ATMPs are available in individual European Union member states via Hospital exemption. Another 31 potential ATMP candidates could be identified in industry-driven phase III research projects. Conclusion: Advanced therapeutic medicinal therapies are still in their early days, but constantly evolving. By 2020, innovative therapies targeting retinal dystrophy, ß-thalassemia, scleroderma, sickle-cell anaemia, adrenoleukodystrophy and leukaemia shall be available on the market.

Keywords: ATMP; Advanced Therapeutic Medicinal Product; Hospital exemption; marketing authorisation; phase III clinical trial.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow chart of clinical trial identification and inclusion.
Figure 2.
Figure 2.
ATMP products applied in individual European member states via Hospital exemption.
Figure 3.
Figure 3.
Potential ATMP candidates in industry-driven phase III clinical trials.
Figure 4.
Figure 4.
Stem cell therapies and potential ATMP candidates applied in academic phase III and IV clinical trials.
See this image and copyright information in PMC

References

    1. European Commission Commission directive 2009/120/EC of 14 December 2009 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use as regards advanced therapy medicinal products. Off J Eur Union. L242/3–12.
    1. Buljovcic Z.European marketing authorisation: a long process. Experiences of small biotech companies with the ATMP regulation. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2011;54(7):831–13. - PubMed
    1. European Medicines Agency Orphan designation: overview. [cited2018November21]: Available from: https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designatio....
    1. gov.uk, GUIDANCE ON THE UK’S ARRANGEMENTS UNDER THE HOSPITAL EXEMPTION SCHEME [cited201821November]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploa...
    1. Pellegrini G, Rama P, Di Rocco A, et al. Concise review: hurdles in a successful example of limbal stem cell-based regenerative medicine. Stem Cells. 2014;32(1):26–34. - PubMed